Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information

Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy; Department of Systems Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy These authors contributed equally to this work. Correspondence to: Marina Talamonti. Department of Systems Medicine, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy. Email: talamonti.marina@gmail.com. Provenance: This is an invited article commissioned by the Academic Editor Dr. Weijun Jiang (Nanjing Normal University, Department of Reproductive and Genetics, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China). Comment on: van Vugt LJ, van den Reek JMPA, Hannink G, et al. Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis. JAMA Dermatol 2019;155:708-15.